Oxford BioTherapeutics has entered a multi‑year collaboration with Bristol Myers Squibb to discover and develop novel T‑cell ...

Bayer has received MHRA approval for Kerendia (finerenone) for adults in the UK with symptomatic chronic heart failure and a left ventricular ejection fraction of 40% or above. Th ...

Subcutaneous delivery shows IV‑level efficacy in moderate to severe TED Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults ...

For decades, MASLD has been described as a ‘silent’ condition because it rarely presents with dramatic liver specific ...

GLP-1 therapies have now advanced far beyond their origins. Originally developed as treatments for type 2 diabetes, they have become one of the most influential forces reshaping consumer behaviour, ...

CatalYm has dosed the first patient in its global GDFATHER-HCC-01 study, a phase 2b trial evaluating visugromab in combination with chemoimmunotherapy for people with unresectable or metastatic ...

For decades, progress in IVF has been driven by improvements in process efficiency rather than advances in biology. Clinics have become better at retrieving eggs, culturing embryos and selecting those ...

Kainova Therapeutics has dosed the first patient in the European expansion of its DOMISOL phase 1/2 trial of DT 7012, a ...